Collectively, our results indicate that lysophospholipid metabolism governs CML stemness in vivo in a manner that is independent of oncogenic BCR–ABL1 signaling. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.